AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04074967 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phase II ARRY-614 + nivolumab+ipilimumab (RCC)
Description: Recommended Phase II dose of ARRY-614 (to be determined) daily in 4-week cycles (± 3 days).~Nivolumab will be dosed according to FDA-approved dosing schedule. Ipilimumab therapy will be dosed according to FDA-approved dosing schedule.
Study NCT01417273 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: vitamin A
Description: 1 cap vitamin A 25000 IU/day for 6 months and 10000 IU/day for next 6 months
Study NCT01417273 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Drug: placebo
Description: 1 cap placebo/day for 12 month
Study NCT02566655 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fucosylated MSC for Osteoporosis
Description: Aproximately 30 days before the infusion of the investigational product, patient bone marrow will be obtained according to standard practice of the Haematology University Hospital Virgen de la Arrixaca (HCUVA).~Mononuclear bone marrow cells will be separated and cultured in GMP conditions to purify and obtain mesenchymal cell established dose range. The infusion day BM-MSCs will be fucosylated and resuspended in saline to a concentration of 5 million cells per 1 mL. Then, the final product will be packaged in syringes for intravenous administration to patients through a peripheral venous access.
Study NCT03750604 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: visceral fat obesity (surface area and function)
Description: WC is evaluated at the midpoint between the lower border of the rib cage and the iliac crest. The surface area of subcutaneous fat (S) and visceral (V) is calculated using slices between L4-L5 and umbilicus according to ct detection fat methods Also bladder wall thickness was calculated by measuring average bladder wall thickness at three different levels.~Subcutaneous fat to visceral fat ratio was calculated. Assays for serum total and high-density lipoprotein cholesterol (HDL-C) and triglyceride (TG) levels were performed in the hospital's chemistry laboratory with an autoanalyzer. VAI was calculated for females as this formula like the previous study.~VAI: WC/ \[36.58 + (1.89 × BMI)\] × TG/0.81 × 1.52/HDL.~And in males:~VAI: WC / \[39.68 + (1.88 x BMI)\] x TG/ 1.03 x 1.31/ HDL WC: waist circumference, BMI: body mass index, TG: triglyceride, HDL: high-density lipoprotein
Study NCT03750604 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: visceral fat obesity (surface area and function)
Description: WC is evaluated at the midpoint between the lower border of the rib cage and the iliac crest. The surface area of subcutaneous fat (S) and visceral (V) is calculated using slices between L4-L5 and umbilicus according to ct detection fat methods Also bladder wall thickness was calculated by measuring average bladder wall thickness at three different levels.~Subcutaneous fat to visceral fat ratio was calculated. Assays for serum total and high-density lipoprotein cholesterol (HDL-C) and triglyceride (TG) levels were performed in the hospital's chemistry laboratory with an autoanalyzer. VAI was calculated for females as this formula like the previous study.~VAI: WC/ \[36.58 + (1.89 × BMI)\] × TG/0.81 × 1.52/HDL.~And in males:~VAI: WC / \[39.68 + (1.88 x BMI)\] x TG/ 1.03 x 1.31/ HDL WC: waist circumference, BMI: body mass index, TG: triglyceride, HDL: high-density lipoprotein
Study NCT00005970 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aromatase Inhibition Therapy
Description: Given orally
Study NCT00005970 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study NCT00005970 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride
Description: Given IV
Study NCT00005970 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT00005970 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV
Study NCT00005970 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen Citrate
Description: Given orally
Study NCT02292082 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine
Study NCT00005970 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Given IV
Study NCT02292082 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Study NCT02292082 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Study NCT02292082 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone
Study NCT01880736 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec
Description: Individual dose adjusted once weekly. IDeg (100 U/mL, 3 mL FlexTouch® pen PDS290) to be administered subcutaneously (under the skin) OD at the same time each day. A maximum of 3 pre-trial oral anti-diabetic drugs (OADs) are allowed during the trial at an unchanged, stable dose level and dosing frequency.
Study NCT02292082 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefazolin
Study NCT02292082 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cefazolin
Study NCT02292082 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Normal saline
Study NCT02292082 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal saline
Study NCT01818869 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD8848
Description: Multiple doses inhaled IMP via a nebulizer
Study NCT01818869 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to match AZD8848
Description: Multiple doses inhaled matching placebo via a nebulizer
Study NCT01917994 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text Messages
Description: The intervention consists of supportive, informational, and motivational text messages three times a week targeting the following domains: promoting a sense of connectedness to the clinic, fostering social support, building empowerment, ameliorating negative affect, cultivating positive affect, and promoting healthy behaviors and adherence to antiretroviral medication.
Study NCT01917994 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Appointment Reminders
Study NCT01917994 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Appointment Reminders
Study NCT02707666 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Neoadjuvant pembrolizumab every 21 days for three cycles
Study NCT02707666 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin and Pemetrexed
Description: Adjuvant chemotherapy with cisplatin and pemetrexed every 21 days for 4 cycles
Study NCT01595282 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac
Description: For subjects weighing over 50 kg, ketorolac 60 mg in 2cc administered via intramuscular injection 30-60 minutes before suction curettage procedure. For subjects weighing 50 kg or less, ketorolac 30 mg in 1 cc administered via intramuscular injection 30-60 minutes before suction curettage procedure
Study NCT01595282 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: For subjects weighing over 50 kg, ibuprofen 800 mg tablet administered orally 60-90 minutes before suction curettage procedure. For subjects weighing 50 kg or less, ibuprofen 600 mg tablet administered orally 60-90 minutes before suction curettage procedure.
Study NCT02574806 — intervention group
Intervention type: PROCEDURE
Intervention: Blood sample and BNP measurement
Description: Blood sample of umbilical artery from umbilical cord immediately after birth.
Study NCT02848560 — intervention group
Intervention type: DRUG
Intervention: Hyperpolarized Xenon
Description: Inhaled contrast for MRI occurring at each of 4 visits.
Study NCT03886246 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spesolimab
Description: Solution for infusion
Study NCT03886246 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spesolimab
Description: Solution for injection
Study NCT02292082 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Study NCT00912964 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirabegron
Description: Mirabegron tablets
Study NCT02292082 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Study NCT02292082 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Study NCT02292082 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Study NCT02292082 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Study NCT02292082 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Study NCT02292082 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 8 MHz. Chiba needle, 22 G / 4 inches
Study NCT00433966 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bivalirudin
Description: Bivalirudin bolus of 0.75 mg/kg IV, followed by an infusion of 1.75 mg/kg/h as soon as logistically feasible (ideally in the emergency room).
Study NCT00433966 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Unfractionated heparin
Description: 60 U/kg of IV heparin, started as soon as possible (ideally in the emergency room).
Study NCT00433966 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bare metal stent
Description: Uncoated bare metal stent
Study NCT00433966 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel-eluting stent
Description: slow rate-release paclitaxel-eluting stent
Study NCT03139643 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive Dissonance
Description: After reading the materials about their chosen behavior, participants will be asked write an essay about their behavior of choice (studying/exercising). For this essay they will be asked to imagine that they have reached their ideal level of academic achievement/fitness, describe what this would look and feel like, and reflect on how this would impact how they view themselves, their relationships, and their day to day life.
Study NCT03139643 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Action Planning
Description: After reading the materials about their chosen behavior, participants will be asked to make a detailed plan for the following two weeks based on the following items taken from a study by Sniehotta and colleagues (2004): 1) when to complete studying/exercise, 2) where to complete studying/exercise, 3) how to complete studying/exercise (e.g., what types of exercise- cardio, class, etc. or what types of studying activities- reading, taking notes, creating outlines, etc.), and 4) how often to complete studying/exercise. Participants will be given a calendar as an aid to planning their behavior.
Study NCT03139643 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Reflection (Control Condition)
Description: After reading the materials about their chosen behavior, participants will be asked to summarize and reflect on what they read.
Study NCT04313400 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1.1% w/w AMTX-100 CF-part1
Description: AMTX-100 CF, topical cream with 1.1% w/w active pharmaceutical ingredient
Study NCT04313400 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Topical cream manufactured to mimic AMTX-100 CF3
Study NCT04313400 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1.1% w/w AMTX-100 CF3-part2
Description: AMTX-100 CF3, topical cream with 1.1% w/w active pharmaceutical ingredient
Study NCT00597623 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Adalimumab (Humira®)
Description: syringes for injections under cutaneous dose = 40mg vol = 0.8 ml
Study NCT00597623 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: syringes under cutaneous vol = 8 ml
Study NCT02924246 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: cholera vaccination
Description: Oral cholera vaccination on day 0 and day 14
Study NCT02924246 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: cholera vaccination
Description: Oral cholera vaccination on day 0 and day 14
Study NCT02924246 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: raw milk
Description: raw milk
Study NCT02924246 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: pasteurized milk
Description: pasteurized milk
Study NCT02924246 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: UHT milk
Description: UHT milk
Study NCT03826654 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: fortified oil
Description: 35 g fortified sunflower oil
Study NCT03826654 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: plain oil
Study NCT03476694 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ultra sound guided supraclavicular brachial plexus block
Description: ultra sound guided supraclavicular brachial plexus block , comparing the volume of 0.75 % ropivacine in sucessful block and hemidiaphragmatic motilty.
Study NCT04094363 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product A
Description: Usual Brand, filtered combustible cigarette
Study NCT03726918 — intervention group
Intervention type: PROCEDURE
Intervention: Surgery for implantation of a prosthesis
Description: Analysis of micro Ribo Nucleic Acid (RNA) expressed by the synoviocytes, osteoblasts and chondrocytes
Study NCT02319616 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clobetasol 0.05% ointment
Description: Blinded, daily application to one arm for a period of fourteen (14) days
Study NCT04094363 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product B
Description: CSD1902-11, an electronic nicotine delivery system
Study NCT04094363 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product C
Description: CSD1902-21, an electronic nicotine delivery system
Study NCT04094363 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product D
Description: 4mg Nicotine gum
Study NCT01351545 — intervention group
Intervention type: DRUG
Intervention: A multicenter access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs)
Description: A multicenter access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs) for transplantation in pediatric and adult patients with hematologic malignancies and other indications
Study NCT03347877 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: autologous osteo-periosteal cylinder graft transplantation
Description: Autologous osteo-periosteal cylinder graft transplantation is a novel treatment for Hepple V osteochondral lesions of the talus.
Study NCT02319616 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Blinded, daily application to one arm for a period of fourteen (14) days
Study NCT03347877 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: autologous osteochondral graft transplantation
Description: Autologous osteochondral graft transplantation is the most common treatment for Hepple V osteochondral lesions of the talus.
Study NCT03347877 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: autologous osteo-periosteal cylinder graft
Description: Autologous osteo-periosteal cylinder graft is taken from ilium.
Study NCT01901497 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nebulizer
Description: 500 mg/4 mL Amikacin nebulized using vibrating mesh nebulizer associated with a single limb bilevel ventilator. The nebulizations are considered as finished when there is no visible evidence of nebulization for a period of 30 seconds.
Study NCT04336722 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Odevixibat
Description: Odevixibat is a small molecule and selective inhibitor of IBAT.
Study NCT04336722 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo identical in appearance to experimental drug (odevixibat).
Study NCT04204278 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Monovisc
Description: A chemically cross-linked sodium hyaluronate supplied as a 4 mL unit dose in a 5 mL glass syringe.
Study NCT02751762 — intervention group
Intervention type: OTHER
Intervention: Observation Only
Description: No Intervention
Study NCT02662062 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200 mg/m2, IV (in the vein) on day 1 every three weeks (Weeks 1, 3, 7, 10, 13, 16 and 19). until progression or unacceptable toxicity develops.
Study NCT02662062 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 35 mg/m2, IV (in the vein) every week for six weeks.
Study NCT02662062 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: 2.00Gy once daily for 32 fractions, 5 fractions/week over six weeks and two days (a total of 64Gy).
Study NCT01651065 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Microclinic Diabetes Education Program
Description: The microclinic intervention leverages different levels of social networks to positively influence behaviors relating to diabetes and other metabolic conditions through small treatment units called, 'microclinic groups (MC),' consisting of 2-6 friends and family members of the same social network, which lead to a larger network of 'classes' and cohorts.~The program provides MC subjects with shared access to health education and group support to promote glycemic and metabolic control through diet, exercise, and treatment adherence. MC members play a role in the collective effort to combat diabetes and solidifying self-management behavioral skills through peer-monitoring and encouragement of lifestyle behaviors.
Study NCT01651065 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Study NCT03670654 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pilates
Description: The Pilates exercises will be performed in 12 weeks with 40-minute sessions, three times a week: 2 at ambulatory and 1 at home. Ambulatory sessions will be supervised by a physical therapist in non-consecutive days. Patients could be grouped in classes with a maximum of 4 subjects. The first two weeks will be spent learning the technique and, in the third week, patients will receive an exercise booklet for in-home training. Will be used the classical solo Pilates exercises, adapted for non-trained individuals. Before and after each session, patients will be evaluated in relation to expiratory peak flow, blood pressure, heart rate and asthma symptoms.
Study NCT03670654 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Muscle stretching
Description: The muscle stretching exercises will be performed in 12 weeks with 40-minute sessions, three times a week: 2 at ambulatory and 1 at home. Ambulatory sessions will be supervised by a physical therapist in non-consecutive days. Patients could be grouped in classes with a maximum of 4 subjects. Patients will practice muscle stretching exercises for principal muscle groups, performed with 3 repetitions, 15 seconds sustain and 1 minute interval. Before and after each session, the patients will be evaluated in relation to expiratory peak flow, blood pressure, heart rate and asthma symptoms.
Study NCT02777047 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Anticoagulation Coordinated Care
Description: see above
Study NCT04607512 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: telaglenastat
Description: glutaminase inhibitor
Study NCT04607512 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: telaglenastat placebo
Description: matching placebo for telaglenastat
Study NCT04607512 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: moxifloxicin
Description: positive control
Study NCT02446678 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PillCam ESO2
Description: Capsule endoscopy
Study NCT04585594 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mi Propio Camino (MPC)
Description: The Mi Propio Camino (MPC) intervention will be comprised of four sessions. Session 1 will encompass: the facts about high blood pressure (BP), understanding blood pressure readings, provide an overview of changes one can make to manage their BP, introduce MPC personal experience monitoring, and usage the mHealth kit. Subsequently, sessions 2-4 will emphasize the benefits of personal experience monitoring through 1) personal insight (finding what works for them) and 2) empowerment to work with their providers. Session 2 will reinforce this by introducing: synergy between medication and lifestyle, principles of heart-healthy eating and physical activity. Session 3 will incorporate discussion of negative beliefs about medication and patient directed lifestyle learning-rotating stations. Lastly, session 4 will introduce the continuation of personal experience monitoring on their own through the use of behavioral strategies for adherence and provider communication strategies.